Muneer Satter left the role of Director at Annexon, Inc. As of November 6, 2026, Annexon, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 10, 2026, naming 1 appointment and 1 departure (Form 8-K, August 10, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Annexon, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Annexon, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-10. It names 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Annexon, Inc. files it.
Also on the record for Annexon, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 13.9% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 6% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11.9% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by Redmile Group, LLC | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 5.4% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Redmile Group, LLC | 9.9% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 7.1% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.1% of the class | 5%+ stakes | Source |
| November 21, 2025 | Stake report, Schedule 13D/A, by Satter Muneer A | 7.2% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 10.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Annexon, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Annexon, Inc. and the records around it.
Annexon, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch Annexon, Inc.
Get an email when Annexon, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Annexon, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Annexon, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Annexon, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-10 | Out | Director | 8-K, 2026-08-10 | ||
| 2026-08-10 | In | 8-K, 2026-08-10 |
Who leads Annexon, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Muneer Satter, departure reported (filed 2026-08-10). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Annexon, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Annexon, Inc., with the record behind each one.
Find candidates like Director at Annexon, Inc.Every change, in the filing's words
Departing: Muneer Satter, Director
(b) Director Resignation On August 10, 2026, Muneer Satter, a member of the board of directors (the "Board") of Annexon, Inc. (the "Company"), notified the Company of his resignation as a member of the Board and as a member of the audit committee of the Board (the "Audit Committee") and as chair of the nominating and corporate governance committee of the Board (the "Nominating Committee"), effective immediately prior to the appointment of a replacement director, Mark S. Blumenkranz, M.D., M.S.S., to the Board.
Appointed: Mark S. Blumenkranz
(d) Director Appointment On August 10, 2026, the Board, based on the recommendation of the Nominating Committee, appointed Mark S. Blumenkranz, M.D., M.S.S., to the Board, effective immediately (the "Effective Date").
- The Company's management and the Board thank Mr. Satter for his more than eleven years of distinguished service on the Board and many positive contributions to the Company.
- Mr. Satter's resignation was not the result of any disagreement with the Company on any matter related to the Company's operations, policies, practices or strategy, the Company's management or the Board.
- Dr. Blumenkranz will serve as a Class II director with a term expiring at the 2028 annual meeting of stockholders and until his successor has been elected and qualified.
- Dr. Blumenkranz was also appointed as a member of the Audit Committee and Science and Technology committee of the Board.
- Pursuant to the Company's non-employee director compensation program (the "NEDC Program"), as a non-employee director, Dr. Blumenkranz will receive (i) a $40,000 annual retainer for his service on the Board, and (ii) on the date of each annual stockholder meeting, an automatic grant of a stock option to purchase 65,000 shares of common stock under the Company's 2020 Incentive Award Plan (the "2020 Plan"), which vests on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting.
Tools for this story
Each opens in a new tab, filled in for Annexon, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.